Compare PRZO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRZO | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 5.3M |
| IPO Year | 2023 | N/A |
| Metric | PRZO | CMND |
|---|---|---|
| Price | $1.19 | $2.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 415.3K | ★ 537.4K |
| Earning Date | 08-28-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,007,440.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.42 | N/A |
| 52 Week Low | $0.53 | $2.36 |
| 52 Week High | $3.16 | $87.20 |
| Indicator | PRZO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 86.20 |
| Support Level | $1.13 | $2.36 |
| Resistance Level | $1.51 | $3.25 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.02 | 0.34 |
| Stochastic Oscillator | 10.29 | 83.36 |
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.